Antiretroviral therapy can reduce human immunodeficiency virus type 1 (HIV-1) viremia to
below the detection limit of ultrasensitive clinical assays (50 copies of HIV-1 RNA/ml). However…

Elite suppressors (ES) are untreated human immunodeficiency virus type 1 (HIV-1)-infected
individuals who control viremia to levels below the limit of detection of current assays. The …

Rare human immunodeficiency virus 1–infected individuals, termed elite suppressors (ES),
maintain plasma virus levels of <50 copies/ml and normal CD4 counts without therapy. The …

The contribution of humoral immune responses to spontaneous control of hepatitis C virus (HCV)
infection remains unclear. We assessed neutralizing antibody (nAb) responses during …

Risk factors for hepatitis C virus (HCV) infection vary, and there were an estimated 1.75 million
new cases worldwide in 2015. The World Health Organization aims for a 90% reduction …

HIV-1 latency in resting CD4 + T cells represents a major barrier to virus eradication in
patients on highly active antiretroviral therapy (HAART). We describe here a novel post-…

Irritable bowel syndrome (IBS) is a common medical condition characterized by chronic,
recurrent, abdominal pain and discomfort, and altered bowel habits that occur in the absence of …

Vaccine‐induced SARS‐CoV‐2 antibody responses are attenuated in solid organ transplant
recipients (SOTRs) and breakthrough infections are more common. Additional SARS‐CoV‐…

Neutralizing antibodies (NAb) against autologous virus can reach high titers in human
immunodeficiency virus type 1 (HIV-1)-infected patients with progressive disease. Less is known …

A stable latent reservoir for human immunodeficiency virus type 1 (HIV-1) in resting memory
CD4 + T cells presents a barrier to eradication of the infection even in patients on highly …